Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.9% – Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price traded down 5.9% on Monday . The company traded as low as $33.35 and last traded at $33.46. 80,931 shares were traded during trading, a decline of 89% from the average session volume of 745,996 shares. The stock had previously closed at $35.54.

Wall Street Analyst Weigh In

Several research firms have issued reports on AGIO. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank boosted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Stock Down 6.8 %

The firm has a market capitalization of $1.90 billion, a PE ratio of 2.92 and a beta of 0.88. The business has a 50-day moving average price of $33.89 and a 200-day moving average price of $42.70.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $33,000. GF Fund Management CO. LTD. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $39,000. Wingate Wealth Advisors Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $53,000. Sterling Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. Finally, KBC Group NV raised its holdings in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 611 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.